JW (Cayman) Therapeutics Co. Ltd. (HK:2126) has released an update.
JW (Cayman) Therapeutics Co. Ltd has announced its board of directors, consisting of one executive director, four non-executive directors, and three independent non-executive directors. The board has established four committees—Audit, Remuneration, Nomination, and Business Development and Strategy—with members and chairpersons assigned to each. This organizational structure highlights the company’s commitment to robust governance and strategic oversight.
For further insights into HK:2126 stock, check out TipRanks’ Stock Analysis page.
